US6228879B1
(en)
*
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
DE60130799T2
(de)
*
|
2000-11-30 |
2008-07-17 |
Children's Medical Center Corp., Boston |
Synthese von 4-aminothalidomid enantiomeren
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
DE10137163A1
(de)
*
|
2001-07-30 |
2003-02-13 |
Bayer Ag |
Substituierte Isoindole und ihre Verwendung
|
AU2002323063B2
(en)
*
|
2001-08-06 |
2007-11-08 |
Entremed, Inc. |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
US7682803B2
(en)
|
2005-10-13 |
2010-03-23 |
Anthrogenesis Corporation |
Immunomodulation using placental stem cells
|
EP2317307B1
(de)
*
|
2002-02-14 |
2013-11-20 |
Ajinomoto Co., Inc. |
Verfahren zur Analyse von Verbindungen mit einer Amino- und/oder Imino-gruppe, und analytisches Reagens dafür
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
WO2003086373A1
(en)
*
|
2002-04-12 |
2003-10-23 |
Celgene Corporation |
Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds
|
AU2006202316B2
(en)
*
|
2002-05-17 |
2008-04-10 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
EP1505973B1
(de)
|
2002-05-17 |
2010-03-03 |
Celgene Corporation |
Kombinationen zur behandlung von multiplem myelom
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
CN101108185A
(zh)
*
|
2002-10-24 |
2008-01-23 |
细胞基因公司 |
用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
KR20050086780A
(ko)
*
|
2002-11-26 |
2005-08-30 |
안트로제네시스 코포레이션 |
세포요법제, 세포요법제 단위 및 이를 이용한 치료방법
|
KR20050100615A
(ko)
*
|
2003-01-14 |
2005-10-19 |
싸이토키네틱스, 인코포레이티드 |
화합물, 조성물 및 방법
|
EP1601248A4
(de)
*
|
2003-02-13 |
2010-01-27 |
Anthrogenesis Corp |
Verwendung von nabelschnurblut zur behandlung von subjekten, die an einer krankheit, einem leiden oder einer störung leiden
|
US7320992B2
(en)
*
|
2003-08-25 |
2008-01-22 |
Amgen Inc. |
Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
CA2808646C
(en)
|
2003-09-17 |
2016-08-23 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
OA13284A
(en)
*
|
2003-11-06 |
2007-01-31 |
Corporation Celgene |
Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
|
EP1694328A4
(de)
*
|
2003-12-02 |
2010-02-17 |
Celgene Corp |
Verfahren und zusammensetzungen zur behandlung und versorgung von hämoglobinopathie und anämie
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
NZ550026A
(en)
*
|
2004-03-22 |
2009-10-30 |
Celgene Corp |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
US20080199422A1
(en)
*
|
2004-04-14 |
2008-08-21 |
Celgene Corporation |
Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline
|
CA2563810A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
JP2005336157A
(ja)
*
|
2004-04-30 |
2005-12-08 |
Arigen Inc |
光学活性サリドマイドおよびその誘導体の製造法
|
CA2565447A1
(en)
*
|
2004-05-05 |
2005-12-01 |
Celgene Corporation |
Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
|
MXPA06014495A
(es)
*
|
2004-06-17 |
2007-03-01 |
Cytokinetics Inc |
Compuestos, composiciones y metodos.
|
US7176222B2
(en)
|
2004-07-27 |
2007-02-13 |
Cytokinetics, Inc. |
Syntheses of ureas
|
CA2579291C
(en)
*
|
2004-09-03 |
2011-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
|
BRPI0518062A
(pt)
*
|
2004-10-28 |
2008-10-28 |
Celgene Corp |
uso de um modulador de pde4, ou um sal, solvato, ou estereoisÈmero farmaceuticamente aceitável do mesmo, e, composição farmacêutica
|
WO2006053160A2
(en)
*
|
2004-11-12 |
2006-05-18 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases
|
CA2588597A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Celgene Corporation |
Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
KR20080026198A
(ko)
*
|
2005-06-30 |
2008-03-24 |
안트로제네시스 코포레이션 |
태반 유도된 콜라겐 바이오패브릭을 사용한 고막의 복원
|
JP5366544B2
(ja)
*
|
2005-06-30 |
2013-12-11 |
セルジーン コーポレイション |
4−アミノ−2−(2,6−ジオキソピペリジン−3−イル)イソインドリン−1,3−ジオン化合物を調製するための方法
|
EP1919500A2
(de)
*
|
2005-07-13 |
2008-05-14 |
Anthrogenesis Corporation |
Behandlung von beingeschwüren mit kollagen-biogewebe aus plazenta
|
WO2007009061A2
(en)
*
|
2005-07-13 |
2007-01-18 |
Anthrogenesis Corporation |
Ocular plug formed from placenta derived collagen biofabric
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
ES2434946T3
(es)
*
|
2005-08-31 |
2013-12-18 |
Celgene Corporation |
Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
|
US8715677B2
(en)
*
|
2005-09-01 |
2014-05-06 |
Celgene Corporation |
Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
US20070161617A1
(en)
*
|
2005-12-15 |
2007-07-12 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
US20070197505A1
(en)
*
|
2005-12-15 |
2007-08-23 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
US7825120B2
(en)
*
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
US20070208000A1
(en)
*
|
2005-12-15 |
2007-09-06 |
Morgan Bradley P |
Certain chemical entities, compositions and methods
|
WO2007078815A2
(en)
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
WO2007078839A2
(en)
*
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
CN101395266B
(zh)
|
2005-12-29 |
2018-06-15 |
人类起源公司 |
胎盘干细胞群
|
CA2633980A1
(en)
*
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
WO2007092569A1
(en)
*
|
2006-02-07 |
2007-08-16 |
Battelle Memorial Institute |
Esters of 5 -hydroxymethylfurfural and methods for their preparation
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
TW200806625A
(en)
*
|
2006-05-26 |
2008-02-01 |
Astrazeneca Ab |
Therapeutic compounds
|
US8435970B2
(en)
*
|
2006-06-29 |
2013-05-07 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
US7993918B2
(en)
|
2006-08-04 |
2011-08-09 |
Anthrogenesis Corporation |
Tumor suppression using placental stem cells
|
WO2008021391A1
(en)
*
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
ES2426350T3
(es)
*
|
2006-08-30 |
2013-10-22 |
Celgene Corporation |
Compuestos de isoindolina sustituidos en 5
|
RU2448101C2
(ru)
*
|
2006-08-30 |
2012-04-20 |
Селджин Корпорейшн |
5-замещенные изоиндолиновые соединения
|
US8877780B2
(en)
*
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
TW200819435A
(en)
*
|
2006-09-15 |
2008-05-01 |
Celgene Corp |
N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
|
WO2008042441A1
(en)
*
|
2006-10-03 |
2008-04-10 |
Anthrogenesis Corporation |
Use of umbilical cord biomaterial for ocular surgery
|
US8071135B2
(en)
|
2006-10-04 |
2011-12-06 |
Anthrogenesis Corporation |
Placental tissue compositions
|
JP5769925B2
(ja)
|
2006-10-06 |
2015-08-26 |
アントフロゲネシス コーポレーション |
ヒト胎盤コラーゲン組成物、並びにそれらの製造方法及び使用方法
|
EP2630959A1
(de)
|
2007-02-12 |
2013-08-28 |
Anthrogenesis Corporation |
Behandlung von Infektionskrankheiten mithilfe von Plazenta-Stammzellen
|
WO2008100497A1
(en)
*
|
2007-02-12 |
2008-08-21 |
Anthrogenesis Corporation |
Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
|
WO2008115516A2
(en)
*
|
2007-03-20 |
2008-09-25 |
Celgene Corporation |
4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
|
US20100172830A1
(en)
*
|
2007-03-29 |
2010-07-08 |
Cellx Inc. |
Extraembryonic Tissue cells and method of use thereof
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
RU2010116271A
(ru)
*
|
2007-09-26 |
2011-11-10 |
Селджин Селльюлар Терапьютикс (Us) |
Ангиогенные клетки из плацентарного перфузата человека
|
CN104211684A
(zh)
|
2007-09-26 |
2014-12-17 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
KR20210127819A
(ko)
|
2007-09-28 |
2021-10-22 |
안트로제네시스 코포레이션 |
인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
|
KR20220098055A
(ko)
*
|
2007-11-07 |
2022-07-08 |
셀룰래리티 인코포레이티드 |
조산 합병증의 치료에 있어서의 제대혈의 용도
|
AU2008325140A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
|
WO2009073146A2
(en)
*
|
2007-11-29 |
2009-06-11 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
|
US7964354B2
(en)
|
2007-12-20 |
2011-06-21 |
Celgene Corporation |
Use of micro-RNA as a biomarker of immunomodulatory drug activity
|
CA2712724A1
(en)
*
|
2008-01-29 |
2009-08-06 |
Celgene Corporation |
Use of lenalidomide or pomalidomide for treating a disease associated with cd59 deficiency
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
KR20210010648A
(ko)
*
|
2008-08-20 |
2021-01-27 |
안트로제네시스 코포레이션 |
개선된 세포 조성물 및 그의 제조 방법
|
RU2558778C2
(ru)
*
|
2008-08-20 |
2015-08-10 |
Антродженезис Корпорейшн |
Лечение инсульта с использованием изолированных плацентарных клеток
|
EP2331109B1
(de)
*
|
2008-08-22 |
2013-05-29 |
Anthrogenesis Corporation |
Verfahren und zusammensetzungen zur behandlung von knochendefekten mit plazenta-zellpopulationen
|
NZ592425A
(en)
*
|
2008-10-29 |
2013-04-26 |
Celgene Corp |
Isoindoline compounds for use in the treatment of cancer
|
EP2367932B1
(de)
|
2008-11-19 |
2019-06-12 |
Celularity, Inc. |
Aus fruchtwasser stammende adhärente zellen
|
NZ592839A
(en)
*
|
2008-11-21 |
2012-10-26 |
Anthrogenesis Corp |
Treatment of diseases, disorders or conditions of the lung using placental cells
|
CA2746221A1
(en)
*
|
2008-12-08 |
2010-07-08 |
Sirtris Pharmaceuticals, Inc. |
Isoindolinone and related analogs as sirtuin modulators
|
AU2010229711B2
(en)
|
2009-03-25 |
2015-06-04 |
Celularity Inc. |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
CN102448472A
(zh)
|
2009-05-25 |
2012-05-09 |
国立大学法人东京工业大学 |
包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物
|
CN101580501B
(zh)
*
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
MX337566B
(es)
|
2010-01-05 |
2016-03-10 |
Celgene Corp |
Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
|
WO2011094181A1
(en)
*
|
2010-01-26 |
2011-08-04 |
Anthrogenesis Corporation |
Treatment of bone-related cancers using placental stem cells
|
RS58523B1
(sr)
|
2010-02-11 |
2019-04-30 |
Celgene Corp |
Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
|
CN107699541A
(zh)
|
2010-04-07 |
2018-02-16 |
人类起源公司 |
使用胎盘干细胞的血管生成
|
US9408831B2
(en)
|
2010-04-07 |
2016-08-09 |
Celgene Corporation |
Methods for treating respiratory viral infection
|
MX2012011543A
(es)
|
2010-04-08 |
2013-05-06 |
Anthrogenesis Corp |
Tratamiento de sarcoidosis empleando celulas madre placentarias.
|
KR20200077613A
(ko)
|
2010-07-13 |
2020-06-30 |
안트로제네시스 코포레이션 |
천연 킬러 세포의 생성 방법
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
WO2012092485A1
(en)
|
2010-12-31 |
2012-07-05 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory rna molecules
|
TWI601722B
(zh)
|
2011-03-11 |
2017-10-11 |
西建公司 |
3-(5-胺基-2-甲基-4-氧基-4h-喹唑啉-3-基)-六氫吡啶-2,6-二酮之固體型式及其醫藥組合物及用途
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
WO2012145309A1
(en)
|
2011-04-18 |
2012-10-26 |
Celgene Corporation |
Biomarkers for the treatment of multiple myeloma
|
US9365640B2
(en)
|
2011-04-29 |
2016-06-14 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
ES2707579T3
(es)
|
2011-06-01 |
2019-04-04 |
Celularity Inc |
Tratamiento del dolor usando citoblastos placentarios
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
US10335482B2
(en)
|
2012-06-06 |
2019-07-02 |
Bionor Immuno As |
Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
|
JP6318152B2
(ja)
|
2012-06-29 |
2018-04-25 |
セルジーン コーポレイション |
セレブロン関連タンパク質を利用して薬物効能を決定する方法
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
AU2014205043B2
(en)
|
2013-01-14 |
2018-10-04 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
JP2016506968A
(ja)
|
2013-02-05 |
2016-03-07 |
アントフロゲネシス コーポレーション |
胎盤由来のナチュラルキラー細胞
|
CA2941560A1
(en)
|
2013-03-14 |
2014-09-25 |
Deuterx, Llc |
3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
EP2970372B1
(de)
|
2013-03-15 |
2020-09-30 |
Celgene Corporation |
Modifizierte t-lymphozyten
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
CN103396397A
(zh)
*
|
2013-08-14 |
2013-11-20 |
中国人民解放军军事医学科学院毒物药物研究所 |
来那度胺衍生物及其作为药物的用途
|
CN103421061A
(zh)
*
|
2013-08-14 |
2013-12-04 |
中国药科大学 |
来那度胺衍生物、其制法及其医药用途
|
WO2015097121A1
(en)
*
|
2013-12-23 |
2015-07-02 |
Norgine B.V. |
Compounds useful as ccr9 modulators
|
KR20220101015A
(ko)
*
|
2014-04-14 |
2022-07-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
JP2017523166A
(ja)
|
2014-07-11 |
2017-08-17 |
ビオノール イミュノ エーエスBionor Immuno As |
ヒト免疫不全ウイルスi(hiv)の病理学的影響を減少及び/若しくは遅延させるか又は後天性免疫不全症候群(aids)を発症するリスクを低減させる方法
|
HUE061382T2
(hu)
|
2014-08-22 |
2023-06-28 |
Celgene Corp |
Eljárás myeloma multiplex kezelésére immunomoduláló vegyületekkel, antestekkel kombinálva
|
PL3214081T3
(pl)
*
|
2014-10-30 |
2021-04-06 |
Kangpu Biopharmaceuticals, Ltd. |
Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
|
CN107257800B
(zh)
|
2014-12-23 |
2020-06-30 |
达纳-法伯癌症研究所股份有限公司 |
通过双功能分子诱导靶蛋白降解的方法
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
BR112017015497A2
(pt)
|
2015-01-20 |
2018-01-30 |
Arvinas, Inc. |
composto, e, composição
|
WO2016177833A1
(en)
|
2015-05-04 |
2016-11-10 |
Bionor Immuno As |
Dosage regimen for hiv vaccine
|
EP3302482A4
(de)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-bindende kinase-1-protacs und zugehörige verfahren zur verwendung
|
EP3313818B1
(de)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Verfahren zur behandlung von kaposi-sarkom oder ksvh-induziertem lymphom unter verwendung immunmodulatorischer verbindungen und verwendungen von biomarkern
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
DK3357513T3
(da)
*
|
2015-09-29 |
2023-11-27 |
Kangpu Biopharmaceuticals Inc |
Farmaceutisk sammensætning og anvendelse deraf
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
CA3020281A1
(en)
*
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
US11192898B2
(en)
*
|
2016-04-06 |
2021-12-07 |
The Regents Of The University Of Michigan |
MDM2 protein degraders
|
RU2752677C2
(ru)
*
|
2016-04-12 |
2021-07-29 |
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган |
Деструкторы белка вет
|
EP3455219A4
(de)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
Amingebundene c3-glutarimiddegronimere für zielproteinabbau
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
EP3454856B1
(de)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclische degronimere für zielproteinabbau
|
EP3455218A4
(de)
|
2016-05-10 |
2019-12-18 |
C4 Therapeutics, Inc. |
Mit c3-kohlenstoff verknüpfte glutarimiddegronimere zum zielproteinabbau
|
WO2018071606A1
(en)
|
2016-10-11 |
2018-04-19 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
US11458123B2
(en)
|
2016-11-01 |
2022-10-04 |
Arvinas Operations, Inc. |
Tau-protein targeting PROTACs and associated methods of use
|
EP3689868B1
(de)
|
2016-12-01 |
2023-09-27 |
Arvinas Operations, Inc. |
Tetrahydronaphthalin- und tetrahydroisochinolinderivate als östrogenrezeptorabbauende mittel
|
JP7227131B2
(ja)
|
2016-12-03 |
2023-02-21 |
ジュノー セラピューティクス インコーポレイテッド |
Car-t細胞の投薬を決定するための方法
|
CA3045508A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
PL3527210T3
(pl)
*
|
2016-12-16 |
2021-11-29 |
Kangpu Biopharmaceuticals, Ltd. |
Kombinacja skojarzona zawierająca związek benzoheterocykliczny i modulator szlaku receptora androgenowego oraz jej zastosowania
|
EP3559006A4
(de)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
Verbindungen und verfahren zum gezielten abbau von fetalen leberkinasepolypeptiden
|
BR112019012682A2
(pt)
|
2016-12-23 |
2019-12-17 |
Arvinas Operations Inc |
moléculas quiméricas visando a proteólise de egfr e métodos associados de uso
|
CA3047784A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
KR20230140606A
(ko)
|
2017-01-26 |
2023-10-06 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
|
KR102125661B1
(ko)
*
|
2017-02-13 |
2020-06-22 |
강푸 바이오파마슈티칼즈 리미티드 |
전립선암 치료용 조합, 약학 조성물 및 치료 방법
|
EP4327878A3
(de)
|
2017-05-01 |
2024-05-01 |
Juno Therapeutics, Inc. |
Kombination aus einer zelltherapie und einer immunmodulatorischen verbindung
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
BR112019025403A2
(pt)
|
2017-06-02 |
2020-08-18 |
Juno Therapeutics Inc |
artigos de fabricação e métodos para tratamento usando terapia celular adotiva
|
WO2018237026A1
(en)
|
2017-06-20 |
2018-12-27 |
C4 Therapeutics, Inc. |
N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
|
JP2020526194A
(ja)
|
2017-06-29 |
2020-08-31 |
ジュノー セラピューティクス インコーポレイテッド |
免疫療法薬と関連する毒性を評価するためのマウスモデル
|
CN109422751B
(zh)
*
|
2017-09-03 |
2022-04-22 |
上海美志医药科技有限公司 |
一类具有降解酪氨酸蛋白激酶jak3活性的化合物
|
EP3679026A1
(de)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimid
|
WO2019043208A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROQUINOLINONES
|
EP3679027A1
(de)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydrobenzimidazolone
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
WO2019089969A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
EP3710002A4
(de)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
Degrader und degrone für gezielten proteinabbau
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
US11299485B2
(en)
|
2018-01-25 |
2022-04-12 |
Fujimoto Co., Ltd. |
Thiophene derivative and use thereof
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
SG11202007495SA
(en)
|
2018-02-21 |
2020-09-29 |
Celgene Corp |
Bcma-binding antibodies and uses thereof
|
WO2019191112A1
(en)
|
2018-03-26 |
2019-10-03 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
CN112218859A
(zh)
|
2018-04-04 |
2021-01-12 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
CN112312904A
(zh)
|
2018-04-16 |
2021-02-02 |
C4医药公司 |
螺环化合物
|
JP7458324B2
(ja)
*
|
2018-04-23 |
2024-03-29 |
セルジーン コーポレイション |
置換された4-アミノイソインドリン-1,3-ジオン化合物、及びリンパ腫の治療のためのそれらの使用
|
EP3578561A1
(de)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiroverbindungen
|
KR20210025061A
(ko)
*
|
2018-06-29 |
2021-03-08 |
다나-파버 캔서 인스티튜트 인크. |
세레블론(crbn)에 대한 리간드
|
WO2020051235A1
(en)
*
|
2018-09-04 |
2020-03-12 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
EP3876958A1
(de)
|
2018-11-08 |
2021-09-15 |
Juno Therapeutics, Inc. |
Verfahren und kombinationen zur behandlung und t-zell-modulation
|
WO2020102195A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
US20220008465A1
(en)
|
2018-11-16 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
SG11202105502RA
(en)
|
2018-11-30 |
2021-06-29 |
Juno Therapeutics Inc |
Methods for treatment using adoptive cell therapy
|
CN109293631B
(zh)
*
|
2018-11-30 |
2020-05-08 |
常州制药厂有限公司 |
3-氨基-n-(2,6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法
|
PE20212198A1
(es)
|
2019-01-29 |
2021-11-16 |
Juno Therapeutics Inc |
Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1)
|
US20230248696A1
(en)
*
|
2019-05-03 |
2023-08-10 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
SG11202112355VA
(en)
|
2019-05-24 |
2021-12-30 |
Biotheryx Inc |
Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
|
MX2021014350A
(es)
|
2019-05-31 |
2022-02-21 |
Celgene Corp |
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
|
JP2022551185A
(ja)
*
|
2019-10-09 |
2022-12-07 |
モンテ ローザ セラピューティクス アーゲー |
イソインドリノン化合物
|
IL293027A
(en)
|
2019-11-19 |
2022-07-01 |
Bristol Myers Squibb Co |
Compounds useful as inhibitors of Helios protein
|
US11883393B2
(en)
|
2019-12-19 |
2024-01-30 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
WO2021231174A1
(en)
|
2020-05-09 |
2021-11-18 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
CN112876414B
(zh)
*
|
2021-01-29 |
2022-09-09 |
河南大学 |
一种基于多胺修饰的萘酰亚胺缀合物、其制备方法及应用
|
WO2022200857A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Monte Rosa Therapeutics Ag |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
WO2022216644A1
(en)
|
2021-04-06 |
2022-10-13 |
Bristol-Myers Squibb Company |
Pyridinyl substituted oxoisoindoline compounds
|
WO2022236339A1
(en)
*
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
CN115504963A
(zh)
*
|
2021-06-22 |
2022-12-23 |
苏州开拓药业股份有限公司 |
一种c-Myc蛋白降解剂
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
AU2023214044A1
(en)
|
2022-01-31 |
2024-08-08 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
CN114656374A
(zh)
*
|
2022-02-22 |
2022-06-24 |
营口兴福化工有限公司 |
2,4-二氯-3-氰基-5-氟苯甲酸合成方法
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
KR20240001072A
(ko)
*
|
2022-06-24 |
2024-01-03 |
주식회사 아이비스바이오 |
신규한 포말리도마이드 유도체 및 이의 제조방법
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
KR20240066904A
(ko)
*
|
2022-11-08 |
2024-05-16 |
주식회사 온코드바이오 |
아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
|